326 related articles for article (PubMed ID: 12846485)
1. Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8.
Flouret G; Chaloin O; Slaninová J
J Pept Sci; 2003 Jun; 9(6):393-401. PubMed ID: 12846485
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of oxytocin featuring replacement with modified beta-mercaptopropionic acids at position 1.
Flouret G; Majewski T; Balaspiri L; Brieher W; Mahan K; Chaloin O; Wilson L; Slaninová J
J Pept Sci; 2002 Jul; 8(7):314-26. PubMed ID: 12148781
[TBL] [Abstract][Full Text] [Related]
3. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
Flouret G; Chaloin O; Borovickova L; Slaninová J
J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
[TBL] [Abstract][Full Text] [Related]
4. Analogues of oxytocin antagonists bearing a ureido group in the amino acid side chain at position 4 or 5.
Flouret G; Chaloin O; Borovickova L; Slaninová J
J Pept Sci; 2006 May; 12(5):347-53. PubMed ID: 16285023
[TBL] [Abstract][Full Text] [Related]
5. Improvement in potency of an oxytocin antagonist after systematic substitutions with L-tryptophan.
Flouret G; Brieher W; Majewski T; Mahan K; Wilson L
J Med Chem; 1991 Jul; 34(7):2089-94. PubMed ID: 2066980
[TBL] [Abstract][Full Text] [Related]
6. Some pharmacological properties of cyclic and linear analogs obtained by substituting each residue of an oxytocin antagonist with D-tryptophan.
Flouret G; Brieher W; Majewski T; Mahan K; Wilson L
Int J Pept Protein Res; 1991 Aug; 38(2):169-75. PubMed ID: 1783491
[TBL] [Abstract][Full Text] [Related]
7. Systematic substitution of an oxytocin antagonist with D-amino acids: unexpected high antagonistic potency of the D-Cys6-substituted analogue.
Flouret G; Majewski T; Brieher W; Wilson L
J Med Chem; 1993 Mar; 36(6):747-9. PubMed ID: 8459401
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activity of oxytocin analogues containing unnatural amino acids in position 9: structure activity study.
Magafa V; Borovicková L; Slaninová J; Cordopatis P
Amino Acids; 2010 May; 38(5):1549-59. PubMed ID: 19885720
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Fragiadaki M; Magafa V; Borovicková L; Slaninová J; Cordopatis P
Eur J Med Chem; 2007 Jun; 42(6):799-806. PubMed ID: 17316912
[TBL] [Abstract][Full Text] [Related]
10. Design of potent oxytocin antagonists featuring D-tryptophan at position 2.
Flouret G; Brieher W; Mahan K; Wilson L
J Med Chem; 1991 Feb; 34(2):642-6. PubMed ID: 1995888
[TBL] [Abstract][Full Text] [Related]
11. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
12. Oxytocin analogues with amide groups substituted by tetrazole groups in position 4, 5 or 9.
Manturewicz M; Grzonka Z; Borovicková L; Slaninová J
Acta Biochim Pol; 2007; 54(4):805-11. PubMed ID: 18084651
[TBL] [Abstract][Full Text] [Related]
13. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
14. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
Goodfellow VS; Marathe MV; Kuhlman KG; Fitzpatrick TD; Cuadrado D; Hanson W; Zuzack JS; Ross SE; Wieczorek M; Burkard M; Whalley ET
J Med Chem; 1996 Mar; 39(7):1472-84. PubMed ID: 8691478
[TBL] [Abstract][Full Text] [Related]
15. Betidamino acid scan of the GnRH antagonist acyline.
Jiang G; Miller C; Koerber SC; Porter J; Craig AG; Bhattacharjee S; Kraft P; Burris TP; Campen CA; Rivier CL; Rivier JE
J Med Chem; 1997 Nov; 40(23):3739-48. PubMed ID: 9371239
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
Chen L; Zoulíková I; Slaninová J; Barany G
J Med Chem; 1997 Mar; 40(6):864-76. PubMed ID: 9083475
[TBL] [Abstract][Full Text] [Related]
17. Magnesium and biological activity of oxytocin analogues modified on aromatic ring of amino acid in position 2.
Slaninová J; Maletínská L; Vondrásek J; Procházka Z
J Pept Sci; 2001 Aug; 7(8):413-24. PubMed ID: 11548057
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability.
Stymiest JL; Mitchell BF; Wong S; Vederas JC
J Org Chem; 2005 Sep; 70(20):7799-809. PubMed ID: 16277299
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity studies of a novel bicyclic oxytocin antagonist.
Smith DD; Slaninova J; Hruby VJ
J Med Chem; 1992 May; 35(9):1558-63. PubMed ID: 1578481
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
